Tag: Quarterly Results

Business Healthcare & Pharmaceuticals News

Gilead Announces 2025 Q3 Results; Lifts EPS Guidance as Strong HIV Sales and Other Revenue Drive

Gilead

Gilead Sciences (GILD) reported strong Q3 2025 financial results, with total revenues of $7.8 billion and non-GAAP diluted EPS jumping 22% to $2.47. The performance was driven by a 4% rise in its core business (excluding Veklury), led by its HIV franchise and $3.7 billion in Biktarvy sales. Despite a decline in Veklury and Cell Therapy revenue, the company raised its full-year 2025 diluted EPS guidance.

Business Healthcare & Pharmaceuticals News

Eli Lilly’s Q3 2025 Results Soar: Revenue Jumps 54% on Blockbuster Demand for GLP-1 Therapies; Full-Year Guidance Raised

Eli Lilly and Company

Eli Lilly reported blockbuster Q3 2025 earnings, with revenue hitting $17.6 billion on 54% year-over-year growth. The financial success was overwhelmingly driven by its incretin portfolio, particularly the high-demand GLP-1 drugs Mounjaro and Zepbound, which saw their sales soar. Following the strong performance and R&D momentum including positive Phase 3 data for the oral obesity drug orforglipron Lilly significantly raised its full-year 2025 revenue and EPS guidance.

Business Healthcare & Pharmaceuticals News

Johnson & Johnson Raises 2025 Sales Outlook on Strong Q3 Performance

JohnsonAndJohnson

Johnson & Johnson announced strong third-quarter 2025 financial results, with reported sales increasing by 6.8% to $24.0 billion. The company’s Innovative Medicine and MedTech divisions both contributed to this growth. As a result of this strong performance, Johnson & Johnson has raised its full-year 2025 sales guidance.

Business Healthcare & Pharmaceuticals News

Gilead Sciences Reports Strong Q2 2025 Results, Raises Full-Year Guidance

Gilead

Gilead Sciences reports a successful second quarter for 2025, with total revenue climbing to $7.1 billion, driven by a 7% increase in its HIV franchise sales. Diluted EPS rose to $1.56. Following these strong results, Gilead has raised its full-year 2025 guidance, now expecting product sales between $28.3 billion and $28.7 billion.

Business Healthcare & Pharmaceuticals News

Eli Lilly Reports Strong Q2 2025 Financial Results with 38% Revenue Growth

Eli Lilly and Company

Eli Lilly and Company reported strong second-quarter 2025 financial results, with worldwide revenue increasing 38% to $15.56 billion. This growth was driven by a 42% increase in volume, particularly from the company’s key products Zepbound and Mounjaro. Reported earnings per share (EPS) for the quarter were $6.29, a 92% increase compared to the same period in 2024. Following these results, Lilly has raised its full-year 2025 revenue guidance to a range of $60.0 billion to $62.0 billion.

Business News

Pfizer Reports Strong Q2 2025 Results, Raises Full-Year EPS Guidance

pfizer news

Pfizer delivered robust Q2 2025 results, reporting $14.7 billion in revenue (up 10% operationally) and $0.78 adjusted EPS. Key drivers included double-digit growth from Comirnaty, Paxlovid and Abrysvo. The company raised its full-year adjusted EPS guidance to $2.90–3.10 while reaffirming revenue outlook of $61.0–64.0 billion, underscoring strong commercial execution and cost-saving initiatives.

Business Healthcare & Pharmaceuticals News

Johnson & Johnson Beats Q2 Estimates, Raises 2025 Outlook on Strong Sales Growth

JohnsonAndJohnson

Johnson & Johnson announced robust second-quarter 2025 financial results, surpassing analyst expectations and raising its full-year guidance. The healthcare giant reported a significant 5.8% increase in sales to $23.7 billion, driven by strong performances in its Innovative Medicine and MedTech segments.